Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses

Stephen Gordon, Rose Malamba, Neema Mthunthama, Elizabeth R. Jarman, Kondwani Jambo, Khuzwayo Jere, Eduard E. Zijlstra, Malcolm E. Molyneux, John Dennis, Neil French

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)

Abstract

We compared the effect of intramuscular vs. inhaled 23-valent pneumococcal capsular polysaccharide vaccine (23-PPV) oil pulmonary mucosal immunoglobulin levels. Bronchoalveolar lavage (BAL) and serum were collected from 33 adults before and I month after injected (n = 16) or inhaled (it = 17) 23-PPV. Levels of pneumococcal capsule-specific IgG and IgA to types 1, 9V and 14 were measured in each sample. Injected 23-PPV produced a significant increase in types 1, 9V and 14 capsule-specific IgG and type I IgA in both serum and BAL (type I geometric mean BAL IgG 9.8 ng/ml post-vaccine vs. 5 ng/ml pre-vaccine, p = 0.01; type 9V geo mean 5.6 ng/ml vs. 2.7 ng/ml, p = 0.001; type 14 geo mean 23.6 ng/ml vs. 6.2 ng/ml, p = 0.02). Inhaled vaccine produced no response in either BAL or serum. (C) 2008 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)5400-5406
Number of pages7
JournalVaccine
Volume26
Issue number42
DOIs
Publication statusPublished - 3 Oct 2008

Keywords

  • Bronchoalveolar lavage
  • Immunoglobulin
  • Inhaled pneumococcal vaccine
  • Lung
  • Mucosa
  • Pneumonia
  • Polysaccharide
  • Streptococcus pneumoniae

Fingerprint

Dive into the research topics of 'Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses'. Together they form a unique fingerprint.

Cite this